CG Oncology (CGON) Stock Analysis & AI Equity Report
CG Oncology (CGON) overview
CG Oncology (CGON) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 4.0m and operating profit of USD -191m; the year-end share price was 41.52 USD and market capitalisation was USD 3,350m. CG Oncology is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get CG Oncology's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About CG Oncology
CG Oncology is a clinical biopharmaceutical company developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer. The company is evaluating the therapy in clinical trials for high-risk and intermediate-risk non-muscle invasive bladder cancer, including as a monotherapy and in combination with another drug. Its activities include clinical development and preparation of a regulatory application for an initial indication.
Generate the CG Oncology report
CG Oncology is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for CG Oncology and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on CG Oncology
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.